Roche Holding Ltd · SIX:RO
Roche — UBS European Conference 2024
19 slides from Roche's conference presentation, Nov 12, 2024
Slide 1: Slide 1
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Opening remarks
Opening remarks Teresa Graham | CEO Roche Pharma UBS European Conference 12 November 2024
Slide 4: Group performance, Strategy & refocusing, Outlook
Group performance Strategy & refocusing Outlook
Slide 5: YTD Sep 2024: Strong growth in both divisions
YTD Sep 2024: Strong growth in both divisions Q3 without significant COVID-19 impact Pharma* Diagnostics* Quarterly sales evolution 2022-2024 Quarterly sales evolution 2022-2024 % CER % CER 30% 30% +24% 20% 20% +12% +9% +10% +10% +9% +9% +7% +7% +7% +7% +8% +8% +7% +8% +8% +9% +7% 10% +6% +4% 10% +4
Slide 6: Key growth drivers of the Roche portfolio
Key growth drivers of the Roche portfolio Significant milestones achieved in Q3 to enable future growth +5% YTD Sep 2024 sales Diagnostics: +8% base business growth (CHFbn, YoY CER growth) (+8%)* Significant launches upcoming Itovebi: US approval in 1L PIK3CA-mut HR+ BC 10.7 Tecentriq Hybreza: US ap
Slide 7: Young portfolio to drive growth in the near- to mid-term
Young portfolio to drive growth in the near- to mid-term 2024 NME update: US approval for Itovebi (inavolisib) in HR+ breast cancer and PiaSky in PNH achieved CHFm % of Pharma Sales2 20.0 56% 18.0 50% 16.0 42% 14.0 12.0 34% 10.0 8.0 1 6.0 4.0 2.0 0.0 YTD Sep 2021 YTD Sep 2022 YTD Sep 2023 YTD Sep 20
Slide 8: 2024 guidance raised at HY
2024 guidance raised at HY Core EPS guidance raised from “broadly in line with sales” to “high single digit Core EPS growth” Group sales growth1 Mid single digit sales growth High single digit Core EPS growth Core EPS growth1 excl. impact from resolution of tax disputes in 2023 Dividend outlook Furt
Slide 9: Group performance, Strategy & refocusing, Outlook
Group performance Strategy & refocusing Outlook
Slide 10: Our new Pharma Strategy
Our new Pharma Strategy Providing clarity and intentional focus to leverage our scientific strengths and impact patients globally Where we play: Priority Therapeutic Areas How we succeed: Core capabilities Neurology Oncology/ Hematology Modalities & Devices Manufacturing Technologies Ophthalmology I
Slide 11: Selecting our therapeutic areas and focus disease areas
Selecting our therapeutic areas and focus disease areas Our focus considers societal burden and transformational potential, as well as Roche’s current capabilities External drivers Internal drivers Burden of disease and Potential to yield Roche’s strengths societal costs transformative medicines ● D
Slide 12: E2E disease areas: Focus on delivering transformative medicines
E2E disease areas: Focus on delivering transformative medicines Discovery, R&D and commercialization resources concentrated on our end-to-end disease areas Selection Implications 5 priority Therapeutic Areas Dedicated research teams to drive novel scientific innovation Discovery Burden of Significan
Slide 13: Pipeline acceleration through partnering and acquisitions
Pipeline acceleration through partnering and acquisitions Key deals completed to complement our pipeline across the Pharma focus therapeutic areas * Dual GLP- Molecular 1/GIP RA & siRNA Anti-TL1A in Wnt agonist Zinc finger glue CDKi ADCs in PYY targeting inflammatory in molecules in degraders in por
Slide 14: Pipeline update: Strengthening the Pharma pipeline
Pipeline update: Strengthening the Pharma pipeline NME changes in Q3 NME and LE (QoQ change, Q3 24 vs Q2 24) Phase Indication RG6434 I Neurology ±0 -4 2 2 2 ±0 LTBR agonist I Solid tumors ±0 6 6 -2 CDK4/2i (RGT-419B)* I HR+ breast cancer ±0 11 8 -1 PiaSky** Reg. PNH ±0 4 1 ±0 71 (-6) 6 ±0 tobemstomi
Slide 15: Group performance, Strategy & refocusing, Outlook
Group performance Strategy & refocusing Outlook
Slide 16: Peak sales potential of key pipeline assets (NMEs and LEs)
Peak sales potential of key pipeline assets (NMEs and LEs) New Molecular Entities (NME) giredestrant prasinezumab astegolimab HR+ BC Parkinson's disease COPD inavolisib fenebrutinib ASO Factor B • 7+ NMEs with CHF >3bn peak Pi3Km BC RMS, PPMS IgAN sales potential per asset divarasib Elevidys1 vamiki
Slide 17: 2025: Significant key newsflow ahead
2025: Significant key newsflow ahead* Compound Indication Milestone inavolisib + palbociclib + fulvestrant 1L PIK3CA-mut HR+ BC EU approval Columvi + GemOx 2L+ DLBCL US/EU approval Lunsumio SC 3L+ FL US/EU approval Elevidys DMD EU approval Regulatory Gazyva Lupus nephritis US/EU filing; US approval
Slide 18: One more IR event in 2024: Roche's Digitalization Day on Nov 25th
One more IR event in 2024: Roche’s Digitalization Day on Nov 25th CVM/EASD Pharma Day Neurology/CTAD Digitalization Day Sep 13 Sep 30 Oct 31 Nov 25 • Key data presented at EASD: • Group & Pharma strategy • Overview of the Roche • Roche digital efforts in Pharma • CT-388 (Ph I cohort 11 & 12 in updat
Slide 19: Doing now what patients need next
Doing now what patients need next